ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Public ClinicalTrials.gov record NCT04602117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Study identification
- NCT ID
- NCT04602117
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Bladder Cancer
- Endometrium Tumor
- Estrogen Receptor Positive Tumor
- GastroEsophageal Cancer
- Gastroesophageal Adenocarcinoma
- HER-2 Protein Overexpression
- HER2 Low
- HER2 Low Breast Cancer
- HER2 Low HR Positive
- HER2 Mutation-Related Tumors
- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER2-positive Metastatic Breast Cancer
- HR Positive
- Hormone Receptor Negative Breast Carcinoma
- Hormone Receptor-positive Breast Cancer
- Metastatic
- Metastatic Breast Cancer
- Metastatic Cancer
- Metastatic Gastrointestinal Carcinoid Tumor
- Ovarian Cancer
- Ovarian Carcinoma
- Progesterone Receptor-positive Breast Cancer
- SYD-985
- SYD985
- Triple Negative Breast Cancer
- Vic-trastuzumab Duocarmazine
Interventions
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2021
- Primary completion
- Nov 16, 2021
- Completion
- Nov 16, 2021
- Last update posted
- Nov 17, 2023
2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04602117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2023 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04602117 live on ClinicalTrials.gov.